Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Abdul Hay on Evaluation of Transplant Eligibility in ALL

March 25th 2020

Mohammad Maher Abdul Hay, MD, discusses the process of evaluating the eligibility of patients with acute lymphoblastic leukemia for transplant.

Dr. Kahl on Treatment Strategies for Indolent Lymphoma

March 25th 2020

Brad Kahl, MD, discusses treatment strategies for patients with indolent lymphoma.

Dr. Radich on Impact of MRD in Acute Vs Chronic Leukemias

March 25th 2020

Jerald P. Radich, MD, discusses the impact of minimal residual disease in patients with acute versus chronic leukemias.

Belantamab Mafodotin Emerging as Novel Option for Relapsed/Refractory Myeloma

March 24th 2020

Sagar Lonial, MD, FACP, discusses the encouraging activity with the BCMA-targeted agent belantamab mafodotin in multiple myeloma.

Dr. Grossbard on the Role of MRD in Follicular Lymphoma

March 24th 2020

Michael L. Grossbard, MD, discusses the role of minimal residual disease in follicular lymphoma.

Dr. Cutler on Optimizing Treatment for Acute and Chronic GVHD

March 24th 2020

Corey S. Cutler, MD, MPH, FRCPC, discusses methods to optimize treatment for patients with acute and chronic graft-versus-host disease.

Dr. Westin on Treatment Challenges in Large Cell Lymphoma

March 24th 2020

Jason Westin, MD, MS, FACP, discusses challenges with treating patients with large cell lymphoma.

BTK Inhibitors Transform Treatment in CLL, MCL, and Waldenstrom Macroglobulinemia

March 23rd 2020

Constantine S. Tam, MD, MBBS, highlights the impact of BTK inhibitors in chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström macroglobulinemia.

Venetoclax Combo Improves Survival in Frontline AML

March 23rd 2020

Venetoclax combined with azacitidine improved overall survival versus azacitidine alone in patients with previously untreated acute myeloid leukemia.

Dr. Tzachanis on Research Regarding Post-CAR T-Cell Therapy Progression in Lymphoma

March 20th 2020

Dimitrios Tzachanis, MD, PhD, discusses research regarding post–CAR T-cell therapy progression in lymphoma.

Exploring the Role of BTK Inhibitors in B-Cell Lymphomas

March 20th 2020

During an OncLive® Scientific Interchange, community and academic oncologists review the current treatment landscape and evaluate therapeutic strategies involving BTK inhibitors in B-cell lymphomas.

Photodynamic Therapy SGX301 Shows Significant Response in Pivotal Phase III CTCL Trial

March 19th 2020

Topline results from the pivotal phase III FLASH trial showed that SGX301 demonstrated strong clinical activity in patients with cutaneous T-cell lymphoma.

Dr. Hamdan on the Potential Use of Brentuximab Vedotin/Nivolumab in Hodgkin Lymphoma

March 19th 2020

Ayad Hamdan, MD, hematologist and associate professor of medicine at Moores Cancer Center at the University of California, San Diego, discusses the potential use of nivolumab (Opdivo) and brentuximab vedotin (Adcetris) in patients with advanced-stage classical Hodgkin lymphoma.

Dr. Rizvi on the ECHELON-1 Trial Follow-Up in Hodgkin Lymphoma

March 19th 2020

Syed Rizvi, MD, discusses the 4-year follow-up data from the ECHELON-1 trial in Hodgkin lymphoma.

Dr. Goodman on the Role of PD-1 Inhibitors in T-Cell Lymphomas

March 19th 2020

Aaron Goodman, MD, discusses the role of PD-1 inhibitors in T-cell lymphomas.

Expert Highlights Multitargeted Treatments in Hematologic Malignancies

March 18th 2020

David S. Hong, MD, discusses the burgeoning role of multitargeted therapeutics in patients with hematologic malignancies.

FDA Grants ALPN-101 Orphan Drug Designations in GVHD

March 18th 2020

The FDA has granted 2 Orphan Drug Designations to ALPN-101 for the prevention and treatment of acute graft-versus-host-disease.

Dr. Miklos on the Results of the ZUMA-2 Trial in MCL

March 18th 2020

David Miklos, MD, discusses the results of the phase II ZUMA-2 trial with KTE-X19 in mantle cell lymphoma.

Dr. Abdul Hay on the Evolving Role of Transplant in ALL

March 18th 2020

Mohammad Maher Abdul Hay, MD, discusses the evolving role of transplant in acute lymphoblastic leukemia.

Dr. Cutler on Treatment Options for Acute and Chronic GVHD

March 18th 2020

Corey S. Cutler, MD, MPH, FRCPC, discusses treatment options for patients with acute and chronic graft-versus-host disease.